Maurocalcine is a highly potent cell-penetrating peptide isolated from the Tunisian scorpion Maurus palmatus. Many cell-penetrating peptide analogues have been derived from the full-length maurocalcine by internal cysteine substitutions and sequence truncation. Herein we have further characterized the cell-penetrating properties of one such peptide, MCa UF1-9, whose sequence matches that of the hydrophobic face of maurocalcine. This peptide shows very favorable cell-penetration efficacy compared to Tat, penetratin or polyarginine. The peptide appears so specialized in cell penetration that it seems hard to improve by site directed mutagenesis. A comparative analysis of the efficacies of similar peptides isolated from other toxin members of the same family leads to the identification of hadrucalcin’s hydrophobic face as an even better CPP. Protonation of the histidine residue at position 6 renders the cell penetration of MCa UF1-9 pH-sensitive. Greater cell penetration at acidic pH suggests that MCa UF1-9 can be used to specifically target cancer cells in vivo where tumor masses grow in more acidic environments.
References
[1]
Fajloun, Z.; Kharrat, R.; Chen, L.; Lecomte, C.; di Luccio, E.; Bichet, D.; El Ayeb, M.; Rochat, H.; Allen, P.D.; Pessah, I.N.; et al. Chemical synthesis and characterization of maurocalcine, a scorpion toxin that activates Ca2+ release channel/ryanodine receptors. FEBS Lett. 2000, 469, 179–185, doi:10.1016/S0014-5793(00)01239-4.
[2]
Mouhat, S.; Jouirou, B.; Mosbah, A.; de Waard, M.; Sabatier, J.M. Diversity of folds in animal toxins acting on ion channels. Biochem J. 2004, 378, 717–726, doi:10.1042/BJ20031860.
[3]
Mosbah, A.; Kharrat, R.; Fajloun, Z.; Renisio, J.G.; Blanc, E.; Sabatier, J.M.; El Ayeb, M.; Darbon, H. A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel. Proteins 2000, 40, 436–442, doi:10.1002/1097-0134(20000815)40:3<436::AID-PROT90>3.0.CO;2-9.
[4]
Zamudio, F.Z.; Gurrola, G.B.; Arevalo, C.; Sreekumar, R.; Walker, J.W.; Valdivia, H.H.; Possani, L.D. Primary structure and synthesis of imperatoxin A (iptx(a)), a peptide activator of Ca2+ release channels/ryanodine receptors. FEBS Lett. 1997, 405, 385–389, doi:10.1016/S0014-5793(97)00227-5.
[5]
Zhu, S.; Darbon, H.; Dyason, K.; Verdonck, F.; Tytgat, J. Evolutionary origin of inhibitor cystine knot peptides. FASEB J. 2003, 17, 1765–1767.
[6]
Shahbazzadeh, D.; Srairi-Abid, N.; Feng, W.; Ram, N.; Borchani, L.; Ronjat, M.; Akbari, A.; Pessah, I.N.; de Waard, M.; El Ayeb, M. Hemicalcin, a new toxin from the iranian scorpion hemiscorpius lepturus which is active on ryanodine-sensitive Ca2+ channels. Biochem. J. 2007, 404, 89–96, doi:10.1042/BJ20061404.
[7]
Schwartz, E.F.; Capes, E.M.; Diego-Garcia, E.; Zamudio, F.Z.; Fuentes, O.; Possani, L.D.; Valdivia, H.H. Characterization of hadrucalcin, a peptide from hadrurus gertschi scorpion venom with pharmacological activity on ryanodine receptors. Br. J. Pharmacol. 2009, 157, 392–403, doi:10.1111/j.1476-5381.2009.00147.x.
[8]
Altafaj, X.; France, J.; Almassy, J.; Jona, I.; Rossi, D.; Sorrentino, V.; Mabrouk, K.; de Waard, M.; Ronjat, M. Maurocalcine interacts with the cardiac ryanodine receptor without inducing channel modification. Biochem. J. 2007, 406, 309–315, doi:10.1042/BJ20070453.
[9]
Szappanos, H.; Smida-Rezgui, S.; Cseri, J.; Simut, C.; Sabatier, J.M.; de Waard, M.; Kovacs, L.; Csernoch, L.; Ronjat, M. Differential effects of maurocalcine on Ca2+ release events and depolarization-induced Ca2+ release in rat skeletal muscle. J. Physiol. 2005, 565, 843–853, doi:10.1113/jphysiol.2005.086074.
[10]
Gurrola, G.B.; Arevalo, C.; Sreekumar, R.; Lokuta, A.J.; Walker, J.W.; Valdivia, H.H. Activation of ryanodine receptors by imperatoxin A and a peptide segment of the II-III loop of the dihydropyridine receptor. J. Biol. Chem. 1999, 274, 7879–7886.
[11]
Esteve, E.; Mabrouk, K.; Dupuis, A.; Smida-Rezgui, S.; Altafaj, X.; Grunwald, D.; Platel, J.C.; Andreotti, N.; Marty, I.; Sabatier, J.M.; et al. Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane. J. Biol. Chem. 2005, 280, 12833–12839.
[12]
Tanabe, T.; Beam, K.G.; Adams, B.A.; Niidome, T.; Numa, S. Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. Nature 1990, 346, 567–569, doi:10.1038/346567a0.
[13]
Tanabe, T.; Beam, K.G.; Powell, J.A.; Numa, S. Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA. Nature 1988, 336, 134–139, doi:10.1038/336134a0.
[14]
Altafaj, X.; Cheng, W.; Esteve, E.; Urbani, J.; Grunwald, D.; Sabatier, J.M.; Coronado, R.; de Waard, M.; Ronjat, M. Maurocalcine and domain a of the II-III loop of the dihydropyridine receptor Cav1.1 subunit share common binding sites on the skeletal ryanodine receptor. J. Biol. Chem. 2005, 280, 4013–4016.
[15]
Chen, L.; Esteve, E.; Sabatier, J.M.; Ronjat, M.; de Waard, M.; Allen, P.D.; Pessah, I.N. Maurocalcine and peptide a stabilize distinct subconductance states of ryanodine receptor type 1, revealing a proportional gating mechanism. J. Biol. Chem. 2003, 278, 16095–16106.
[16]
Poillot, C.; Dridi, K.; Bichraoui, H.; Pecher, J.; Alphonse, S.; Douzi, B.; Ronjat, M.; Darbon, H.; de Waard, M. D-maurocalcine, a pharmacologically inert efficient cell-penetrating peptide analogue. J. Biol. Chem. 2010, 285, 34168–34180, doi:10.1074/jbc.M110.104919.
[17]
Mabrouk, K.; Ram, N.; Boisseau, S.; Strappazzon, F.; Rehaim, A.; Sadoul, R.; Darbon, H.; Ronjat, M.; de Waard, M. Critical amino acid residues of maurocalcine involved in pharmacology, lipid interaction and cell penetration. Biochim. Biophys. Acta 2007, 1768, 2528–2540, doi:10.1016/j.bbamem.2007.06.030.
[18]
Ram, N.; Weiss, N.; Texier-Nogues, I.; Aroui, S.; Andreotti, N.; Pirollet, F.; Ronjat, M.; Sabatier, J.M.; Darbon, H.; Jacquemond, V.; et al. Design of a disulfide-less, pharmacologically-inert and chemically-competent analog of maurocalcine for the efficient transport of impermeant compounds into cells. J. Biol. Chem. 2008, 283, 27048–27056, doi:10.1074/jbc.M804727200.
[19]
Poillot, C.; Bichraoui, H.; Tisseyre, C.; Bahemberae, E.; Andreotti, N.; Sabatier, J.M.; Ronjat, M.; de Waard, M. Small efficient cell-penetrating peptides derived from scorpion toxin maurocalcine. J. Biol. Chem. 2012, 287, 17331–17342, doi:10.1074/jbc.M112.360628.
[20]
Aroui, S.; Brahim, S.; de Waard, M.; Breard, J.; Kenani, A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett. 2009, 285, 28–38, doi:10.1016/j.canlet.2009.04.044.
[21]
Aroui, S.; Brahim, S.; de Waard, M.; Kenani, A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study. Biochem. Biophys. Res. Commun. 2010, 391, 419–425, doi:10.1016/j.bbrc.2009.11.073.
[22]
Aroui, S.; Brahim, S.; Hamelin, J.; de Waard, M.; Breard, J.; Kenani, A. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous trail-induced apoptosis. Apoptosis 2009, 14, 1352–1365, doi:10.1007/s10495-009-0397-8.
[23]
Aroui, S.; Ram, N.; Appaix, F.; Ronjat, M.; Kenani, A.; Pirollet, F.; de Waard, M. Maurocalcine as a non-toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231. Pharm. Res. 2009, 26, 836–845, doi:10.1007/s11095-008-9782-1.
[24]
Ram, N.; Texier-Nogues, I.; Pernet-Gallay, K.; Poillot, C.; Ronjat, M.; Andrieux, A.; Arnoult, C.; Daou, J.; de Waard, M. In vitro and in vivo cell delivery of quantum dots by the cell penetrating peptide maurocalcine. Int. J. Biomed. Nanosci. Nanotechnol. 2011, 2, 12–32, doi:10.1504/IJBNN.2011.038464.
[25]
Stasiuk, G.J.; Tamang, S.; Imbert, D.; Poillot, C.; Giardiello, M.; Tisseyre, C.; Barbider, E.L.; Fries, P.H.; de Waard, M.; Reiss, P.; Mazzanti, M. Cell-permeable ln(III) chelate-functionalized InP quantum dots as multimodal imaging agents. ACS Nano 2011, 5, 8193–8201, doi:10.1021/nn202839w.
[26]
Ram, N.; Aroui, S.; Jaumain, E.; Bichraoui, H.; Mabrouk, K.; Ronjat, M.; Lortat-Jacob, H.; de Waard, M. Direct peptide interaction with surface glycosaminoglycans contributes to the cell penetration of maurocalcine. J. Biol. Chem. 2008, 283, 24274–24284, doi:10.1074/jbc.M709971200.
[27]
Boisseau, S.; Mabrouk, K.; Ram, N.; Garmy, N.; Collin, V.; Tadmouri, A.; Mikati, M.; Sabatier, J.M.; Ronjat, M.; Fantini, J.; et al. Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Biochim. Biophys. Acta 2006, 1758, 308–319, doi:10.1016/j.bbamem.2006.02.007.
[28]
Jones, A.T.; Sayers, E.J. Cell entry of cell penetrating peptides: Tales of tails wagging dogs. J. Control. Release 2012, 161, 582–591, doi:10.1016/j.jconrel.2012.04.003.
[29]
Lindgren, M.; Hallbrink, M.; Prochiantz, A.; Langel, U. Cell-penetrating peptides. Trends Pharmacol. Sci. 2000, 21, 99–103, doi:10.1016/S0165-6147(00)01447-4.
[30]
Lundberg, P.; Langel, U. A brief introduction to cell-penetrating peptides. J. Mol. Recognit. 2003, 16, 227–233, doi:10.1002/jmr.630.
[31]
Mano, M.; Teodosio, C.; Paiva, A.; Simoes, S.; Pedroso de Lima, M.C. On the mechanisms of the internalization of s4(13)-pv cell-penetrating peptide. Biochem. J. 2005, 390, 603–612, doi:10.1042/BJ20050577.
[32]
Gurrola, G.B.; Capes, E.M.; Zamudio, F.Z.; Possani, L.D.; Valdivia, H.H. Imperatoxin A, a cell-penetrating peptide from scorpion venom, as a probe of Ca-release channels/ryanodine receptors. Pharmaceuticals (Basel) 2010, 3, 1093–1107.
[33]
El-Hayek, R.; Lokuta, A.J.; Arevalo, C.; Valdivia, H.H. Peptide probe of ryanodine receptor function. Imperatoxin A, a peptide from the venom of the scorpion pandinus imperator, selectively activates skeletal-type ryanodine receptor isoforms. J. Biol. Chem. 1995, 270, 28696–28704.
[34]
Garcia-Martin, M.L.; Herigault, G.; Remy, C.; Farion, R.; Ballesteros, P.; Coles, J.A.; Cerdan, S.; Ziegler, A. Mapping extracellular pH in rat brain gliomas in vivo by 1H magnetic resonance spectroscopic imaging: Comparison with maps of metabolites. Cancer Res. 2001, 61, 6524–6531.
